MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its holdings in Jazz Pharmaceuticals by 14.1%, now owning 52,475 shares valued at approximately $6.5 million.
• In the quarterly earnings report, Jazz Pharmaceuticals posted an EPS of -$8.25, missing the consensus estimate and reflecting a negative net margin of 9.91%.
• Analysts have a consensus rating of "Moderate Buy" for Jazz Pharmaceuticals, with a target price range showing potential growth, particularly from firms like Royal Bank Of Canada raising their target to $151.00.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. trimmed its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 14.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,475 shares of the specialty pharmaceutical company's stock after selling 8,604 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.09% of Jazz Pharmaceuticals worth $6,515,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $25,000. Elequin Capital LP raised its position in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares during the last quarter. Parallel Advisors LLC raised its position in Jazz Pharmaceuticals by 85.6% in the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 119 shares during the last quarter. Picton Mahoney Asset Management raised its position in Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after buying an additional 269 shares during the last quarter. Finally, Spire Wealth Management raised its position in Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after buying an additional 161 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of analyst reports. Morgan Stanley increased their price target on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price target for the company. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Truist Financial upped their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Finally, The Goldman Sachs Group upped their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Fourteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $178.67.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $1.32 during trading hours on Tuesday, hitting $126.54. The company had a trading volume of 649,537 shares, compared to its average volume of 679,407. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The firm has a 50 day simple moving average of $119.30 and a 200 day simple moving average of $116.30. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of -18.80, a PEG ratio of 7.76 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the business earned $5.30 EPS. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.